Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.
Selga, Daina LU ; Segelmark, Mårten LU ; Gunnarsson, Lena LU and Hellmark, Thomas LU
(2010)
In Clinical and Experimental Immunology
160.
p.318-324
- Abstract
- Summary Anti-neutrophil cytoplasmic antibodies against proteinase 3 (PR3-ANCA) are used as diagnostic tools for patients with small vessel vasculitis (AASV). We have produced chimeric mouse/human PR3 molecules and investigate changes in reactivity over time and the possible relationship between epitope specificity and clinical course. Thirty-eight PR3-ANCA-positive patients diagnosed between 1990 and 2003 were followed until December 2005. Plasma was collected at each out-patient visit and older samples were retrieved retrospectively. Patients reacted with multiple epitopes at the time of diagnosis. At subsequent relapses 12 patients shifted reactivity, in 11 cases from epitopes located in the C-terminal towards epitopes in the N-terminal.... (More)
- Summary Anti-neutrophil cytoplasmic antibodies against proteinase 3 (PR3-ANCA) are used as diagnostic tools for patients with small vessel vasculitis (AASV). We have produced chimeric mouse/human PR3 molecules and investigate changes in reactivity over time and the possible relationship between epitope specificity and clinical course. Thirty-eight PR3-ANCA-positive patients diagnosed between 1990 and 2003 were followed until December 2005. Plasma was collected at each out-patient visit and older samples were retrieved retrospectively. Patients reacted with multiple epitopes at the time of diagnosis. At subsequent relapses 12 patients shifted reactivity, in 11 cases from epitopes located in the C-terminal towards epitopes in the N-terminal. Patients with reactivity against N-terminal parts of PR3 at diagnosis had a significantly lower relapse rate, 30% compared to 78% in the group with predominantly C-terminal reactivity (P = 0.04). The reactivity pattern did not correlate to outcome measured as death, end-stage renal disease or vasculitis activity index score (VDI) at 5 years. Further research is necessary to conclude if this is a general phenomenon. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1541283
- author
- Selga, Daina
LU
; Segelmark, Mårten
LU
; Gunnarsson, Lena
LU
and Hellmark, Thomas
LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical and Experimental Immunology
- volume
- 160
- pages
- 318 - 324
- publisher
- British Society for Immunology
- external identifiers
-
- wos:000277403100003
- pmid:20059480
- scopus:77952196152
- pmid:20059480
- ISSN
- 0009-9104
- DOI
- 10.1111/j.1365-2249.2009.04063.x
- language
- English
- LU publication?
- yes
- id
- 415186d9-97ad-49bd-8494-d05bc81c9dac (old id 1541283)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20059480?dopt=Abstract
- date added to LUP
- 2016-04-04 07:19:02
- date last changed
- 2022-01-29 02:00:28
@article{415186d9-97ad-49bd-8494-d05bc81c9dac,
abstract = {{Summary Anti-neutrophil cytoplasmic antibodies against proteinase 3 (PR3-ANCA) are used as diagnostic tools for patients with small vessel vasculitis (AASV). We have produced chimeric mouse/human PR3 molecules and investigate changes in reactivity over time and the possible relationship between epitope specificity and clinical course. Thirty-eight PR3-ANCA-positive patients diagnosed between 1990 and 2003 were followed until December 2005. Plasma was collected at each out-patient visit and older samples were retrieved retrospectively. Patients reacted with multiple epitopes at the time of diagnosis. At subsequent relapses 12 patients shifted reactivity, in 11 cases from epitopes located in the C-terminal towards epitopes in the N-terminal. Patients with reactivity against N-terminal parts of PR3 at diagnosis had a significantly lower relapse rate, 30% compared to 78% in the group with predominantly C-terminal reactivity (P = 0.04). The reactivity pattern did not correlate to outcome measured as death, end-stage renal disease or vasculitis activity index score (VDI) at 5 years. Further research is necessary to conclude if this is a general phenomenon.}},
author = {{Selga, Daina and Segelmark, Mårten and Gunnarsson, Lena and Hellmark, Thomas}},
issn = {{0009-9104}},
language = {{eng}},
pages = {{318--324}},
publisher = {{British Society for Immunology}},
series = {{Clinical and Experimental Immunology}},
title = {{Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.}},
url = {{http://dx.doi.org/10.1111/j.1365-2249.2009.04063.x}},
doi = {{10.1111/j.1365-2249.2009.04063.x}},
volume = {{160}},
year = {{2010}},
}